FDA Approves Ryzumvi (Phentolamine Ophthalmic Solution) for Presbyopia Treatment in Adults

The U.S. Food and Drug Administration (FDA) has approved phentolamine ophthalmic solution 0.75% (Ryzumvi), developed by Opus Genetics, for the treatment of presbyopia (age-related near vision loss) in adults. The approval is based on positive results from the Phase 3 VEGA-2 and VEGA-3 trials, which met their primary and key secondary endpoints. This provides eye care providers with a new pharmacologic option for managing presbyopia.